State of Research
Quality of Conclusions
TBD Papers studying this directly
TBD Companies working on this
Make Blossom Sustainable
Blossom is free to use and will always be.
Supporting Blossom makes this possible. When you support Blossom for €20/month, you get access to our downloadable files, influence over the direction of our 'psychedelics and ...' pages, and future projects.
Our vision is that psychedelics can be used worldwide to better the lives of as many as 450 million people who suffer from mental health problems. Our information hopes to make that vision come to life just a little faster.
Here will be a narrative, readable, summary of the research.
In our literature study we came across the following studies of note. Browse the meta, review, commentary articles for an overview. Check out the individual studies for specific experiments and observations.
Dimethyltryptamine (DMT): a biochemical Swiss Army knife in neuroinflammation and neuroprotection?
2016 | Frecska, E., Szabo, A.
This commentary reviews the role of DMT as an endogenous ligand of the Sigma-1 receptor, and although the exact physiological role of endogenous DMT is yet to be identified, there is evidence that suggests that it can modulate immune responses through the suppression of inflammatory cytokines. These neuroprotective and neuroregenerative effects may render DMT a potentially useful therapeutic tool in a broad range of chronic inflammatory and autoimmune diseases.
A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity
2013 | Frecska, E., Luna, L. E., McKenna, D., Szabo, A., Winkelman, M. J.
This review (2012) postulates that DMT may play a role in cell protection, regeneration, and immunity through activation of a cell-endogenous sigma-1 receptor pathway which regulates oxidative stress-induced changes at the endoplasmic reticulum–mitochondria interface. Supportive experimental data are still necessary for advancing the outlined concepts, such as the endogenous role of DMT or the immunoprotective benefits of exogenous DMT ingested in larger quantities.
Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities
2015 | Szabo, A.
This review (2015) describes the immunomodulatory potential of classical serotonergic psychedelics (DMT, LSD, MDMA, etc) from a perspective of molecular immunology and pharmacology. With a particular focus on functional interaction of serotonin and sigma-1 receptors and cross-talk with toll-like and RIG-I-like pattern-recognition receptor-mediated signalling.
Psychedelics as a Novel Approach to Treating Autoimmune Conditions
2020 | Szabo, A., Thompson, C.
This literature review (2020) argues that psychedelics may be used to treat autoimmune conditions. This may be done via inflammatory pathways, immune modulation or other methods.
Structure–Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore
2020| Billac, G. B., Cormier, S. A., Flanagan, T. W., Landry, A. N., Sebastian, M. N.
This animal study (n=52) investigated structure−activity relationships between 5-HT2A receptor agonists within a novel rat model of allergic asthma and identified that phenylalkylamine structure 2,5-dimethoxyphenethylamine (2C-H) mediated anti-inflammatory activity. There was no apparent correlation between behavioral and anti-inflammatory effects, which indicates distinct structural features of 5-HT2A receptor activity that can be utilized for the development of asthma treatments independent of subjective psychedelic effects.
The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization
2016| Bokor, P., Frecska, E., Winkelman, M. J.
This review (2016) examines the therapeutic potential of ayahuasca based on a summary of its neurobiological, neuroregenerative, and psychophysiological mechanisms and effects on vegetative states and the central nervous system. It emphasizes highlights the therapeutic utility of ayahuasca on a biological level as an anti-inflammatory agonist of the Sigma-1 receptor while incorporating its effects on higher-order psychotherapeutic effects within a bio-psycho-socio-spiritual model.
Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects
2016| Dolder, P. C., Kratschmar, D. V., Liechti, M. E., Odermatt, A., Rentsch, K. M., Schmid, Y., Strajhar, P.
This randomized, double‐blind, placebo‐controlled, cross‐over study (n=16) investigated the effects of LSD (200μg) on the plasma concentration-time profiles of steroid levels. LSD induced significant effects on plasma glucocorticoids, including cortisol and particularly corticosterone, which was also closely related to the subjective effects of LSD. The glucocorticoid response to LSD showed no acute pharmacological tolerance, in contrast to the glucocorticoid response to MDMA.
The DMT and Psilocin Treatment Changes CD11b+ Activated Microglia Immunological Phenotype
2021| Figiel, M., Klimczak, A., Kozłowska, U., Wiatr, K.
This study on neuronal-glial cells (CD11b+ microglia, from mice) found that the direct application of psilocin (a metabolite of psilocybin) and DMT, led to increased capacity for the cells to fulfill their immune responses. Specifically, it reduced levels of TLR4, p65, CD80 proteins (markers of the immune response), and upregulated TREM2 (neuroprotective receptor).
This section compares the research with psychedelics to other therapies, medicines, or treatments.
This section highlights the various measures used and their use in research.
Who are the top researches in this area, the ones who have done the groundbreaking research.
What do we not know at this time? Where are the gaps in our knowledge and are we closing it?
The companies that are actively engaged in researching this topic or (planning to) provide therapy focussed on this topic.
This section highlights everything done outside of academia, from popular press to books and non academic research.